Monoclonal antibody against human oxidized low-density lipoprotein and its application
By screening for highly active oxLDL antigens to prepare highly specific and high-affinity anti-oxLDL monoclonal antibodies, the problem of low accuracy in existing detection methods has been solved, achieving high sensitivity and specificity for the detection of oxLDL, which is suitable for the early diagnosis and monitoring of cardiovascular and cerebrovascular diseases.
Patent Information
- Application Number
- CN202410650630.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-05-24
AI Technical Summary
Existing oxLDL detection methods suffer from problems such as long reaction times, complex operation, low accuracy of detection results, and large differences in results between different methods. This is mainly due to the lack of highly specific and high-affinity monoclonal antibodies, which leads to inaccurate oxLDL content determination.
By screening highly active oxLDL antigens as immunogens and screening antigens, high-specificity and high-affinity anti-oxLDL monoclonal antibodies were prepared and screened. Hybridoma cell lines were used to prepare and apply them to the double-antibody sandwich detection method to improve detection sensitivity and specificity.
It achieves high sensitivity and specificity for the detection of oxLDL, significantly improves the limit of detection, and is superior to existing commercial kits, making it suitable for the early diagnosis and monitoring of cardiovascular and cerebrovascular diseases.
Smart Images

Figure CN118459581B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a monoclonal antibody against human oxidized low-density lipoprotein (oxLDL) and an application thereof. Background Art
[0002] Oxidized low-density lipoprotein (oxLDL) is a product formed after low-density lipoprotein (LDL) undergoes a series of oxidation reactions in the body. A large amount of polyunsaturated fatty acids in LDL undergo peroxidation reactions under the action of excessive free radicals and other oxidants to generate malondialdehyde, which oxidatively modifies the lysine residues on apolipoprotein B. When the amount of lysine oxidative modification exceeds a certain amount, a new antigenic epitope will be formed, i.e., oxidized low-density lipoprotein. oxLDL cannot be recognized by LDL receptors, resulting in slow degradation through the receptor pathway. Instead, it is mainly recognized and taken up by scavenger receptors expressed on the surface of macrophages and vascular endothelium, entering macrophages at a speed several times that of natural LDL. In addition, oxLDL can resist degradation by lysosomal enzymes and proteases, leading to the accumulation of cholesterol in cells and prompting macrophages to form foam cells. Foam cells are an early form of atherosclerosis and a key factor in atherosclerosis, among which oxidized low-density lipoprotein is a key protein in atherosclerosis. Therefore, oxLDL is an important biomarker for the early diagnosis of cardiovascular and cerebrovascular diseases. The detection of oxLDL levels is of great significance for the prevention, monitoring, treatment and early diagnosis of cardiovascular and cerebrovascular diseases.
[0003] At present, the detection methods of oxLDL include the conjugated diene method based on chemical principles and the thiobarbituric acid reactant chemical determination method. Such methods have the disadvantages of long reaction time, complex operation and low accuracy of detection results; the relative electrophoretic migration rate method based on physical property changes also has the above shortcomings; there are also immunological detection methods based on antigen-antibody reaction, including enzyme-linked immunosorbent assay, chemiluminescence method, etc., that is, the use of specific antibodies to achieve oxLDL content determination. The only detection method available in clinical practice is immunological detection method. However, the current clinical detection of oxLDL faces difficulties, with few available detection reagents, large differences in detection results of different methods, and inaccurate content determination. The main reason is that oxidized low-density lipoprotein has low stability, different oxidation degrees, many cross-reactive substances, and it is not easy to prepare highly specific and high-affinity monoclonal antibodies. Therefore, existing immunoassay reagents mostly use polyclonal antibodies or monoclonal antibodies against apolipoprotein apoB, and apolipoprotein apoB is a common component of LDL and oxLDL. The use of monoclonal antibodies against apolipoprotein apoB for quantitative determination of oxLDL components causes inaccurate detection results. Therefore, there is an urgent need to prepare highly specific and high-affinity anti-oxLDL monoclonal antibodies in order to achieve accurate quantification of oxLDL and provide technical support for early diagnosis, prevention, treatment and monitoring of cardiovascular and cerebrovascular diseases.
[0004] In order to make up for the above shortcomings, the present invention is designed to first detect and screen the commercial oxLDL antigen, obtain two highly active oxLDL antigens as immunogens for preparing antibodies and antigens for screening antibodies, and then use a variety of lipoprotein components with structural compositions similar to oxLDL and prone to cross-reaction to screen monoclonal antibodies prepared by immunizing mice, obtain highly specific and high-affinity monoclonal antibodies that only recognize oxLDL antigens, and provide key antibody raw materials for the specific quantitative determination of oxLDL. Summary of the invention
[0005] To this end, the purpose of the present invention is to prepare monoclonal antibodies by screening two highly active oxLDLs as immunization antigens and screening antigens respectively, immunizing mice, and then using a variety of lipoprotein components that are prone to cross-reaction to specifically screen the monoclonal antibodies, to provide anti-oxLDL monoclonal antibodies prepared using fused hybridoma cell lines, and the monoclonal antibodies obtained through experiments can recognize natural oxLDL and do not cross-react with other lipoproteins, have good specificity and affinity, can be used to detect oxLDL, and for preparing products for detecting oxLDL.
[0006] Therefore, one aspect of the present invention relates to an anti-oxLDL monoclonal antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3, and the light chain variable region comprises CDR1, CDR2 and CDR3, wherein:
[0007] The amino acid sequence of the heavy chain CDR1 is the sequence shown in SEQ ID NO.2 or an amino acid sequence having one conservative amino acid substitution compared with the sequence shown in SEQ ID NO.2;
[0008] The amino acid sequence of the heavy chain CDR2 is the sequence shown in SEQ ID NO.3 or an amino acid sequence having one conservative amino acid substitution compared with the sequence shown in SEQ ID NO.3;
[0009] The amino acid sequence of the heavy chain CDR3 is the sequence shown in SEQ ID NO.4 or an amino acid sequence having one conservative amino acid substitution compared with the sequence shown in SEQ ID NO.4;
[0010] The amino acid sequence of the light chain CDR1 is the sequence shown in SEQ ID NO.6 or an amino acid sequence having one conservative amino acid substitution compared with the sequence shown in SEQ ID NO.6;
[0011] The amino acid sequence of the light chain CDR2 is LVS or an amino acid sequence having one conservative amino acid substitution compared to the sequence LVS;
[0012] The amino acid sequence of the light chain CDR3 is the sequence shown in SEQ ID NO.7 or an amino acid sequence having one conservative amino acid substitution compared with the sequence shown in SEQ ID NO.7.
[0013] In a further aspect, the present invention also relates to a monoclonal antibody or an antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is the sequence shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is the sequence shown in SEQ ID NO.5.
[0014] The present invention also relates to the above-mentioned monoclonal antibody or its antigen-binding fragment, wherein the antibody or antigen-binding fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a single-chain antibody or a humanized antibody, and these antibodies or antigen-binding fragments can recognize and bind to human oxLDL because they retain the variable regions of the heavy chain and the light chain.
[0015] In addition, the present invention also relates to a nucleic acid molecule comprising a nucleic acid encoding the above-mentioned antibody or its antigen-binding fragment, and an expression vector comprising the above-mentioned nucleic acid molecule, wherein the expression vector is capable of expressing the above-mentioned antibody or its antigen-binding fragment. At the same time, the present invention also relates to a recombinant comprising the above-mentioned nucleic acid molecule or the above-mentioned expression vector, which can produce the above-mentioned antibody or its antigen-binding fragment. On the other hand, the present invention relates to a monoclonal antibody hybridoma cell line against human oxLDL, wherein the monoclonal antibody hybridoma cell line secretes the above-mentioned monoclonal antibody. Further, the present invention relates to a monoclonal antibody hybridoma cell line against human oxLDL, wherein the monoclonal antibody hybridoma cell line is a mouse hybridoma cell line DF868, and the deposit number is CGMCC No.45832.
[0016] In another aspect, the present invention relates to the use of the above monoclonal antibody or its antigen-binding fragment in the preparation of a product for detecting oxLDL. Further, the present invention relates to a kit for detecting human oxLDL, the kit comprising the above monoclonal antibody or its antigen-binding fragment for recognizing and binding human oxLDL.
[0017] Description of biological material deposit
[0018] The monoclonal antibody hybridoma cell line of the present invention: mouse hybridoma cell line DF868, is deposited in the General Microbiology Center of China National Microbiological Culture Collection (CGMCC), the registration number of the collection center is CGMCC No.45832, and the deposit date is March 27, 2024. The address of the General Microbiology Center of China National Microbiological Culture Collection is: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Postal Code 100101. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 This is a graph showing the results of the rabbit anti-oxLDL polyclonal antibody titer test.
[0020] Figure 2 This is a graph showing the results of the specificity evaluation of anti-oxLDL monoclonal antibodies.
[0021] Figure 3 This is a diagram showing the subtype identification results of the anti-oxLDL monoclonal antibody DF868. DETAILED DESCRIPTION
[0022] The purpose of the present invention is to prepare monoclonal antibodies by using two highly active oxLDLs screened as immune antigens and screening antigens, respectively, to immunize mice, and then use a variety of cross-reactive lipoprotein components to specifically screen the monoclonal antibodies, to provide an anti-oxLDL monoclonal antibody prepared by using a fused hybridoma cell line, and the anti-oxLDL monoclonal antibody can recognize human oxLDL. The specific preparation process is (see Example 1 for details), using an oxLDL determination kit to detect commercial oxLDL antigens, selecting two oxLDL antigens with high activity, using one of them as an immunogen and the other as a monoclonal antibody screening antigen, and using a variety of cross-reactive lipoprotein components to specifically screen the monoclonal antibodies, and obtaining a mouse hybridoma cell line expressing a high-affinity and high-specificity monoclonal antibody, named DF868, and the minimum detection limit of the double antibody sandwich detection method using it as a coating antibody is 2ng / mL, which is significantly higher than the commercial kit, indicating that the high-affinity and high-specificity anti-human oxLDL monoclonal antibody DF868 of the present invention can be used for the determination of oxLDL content in human blood samples, with very high sensitivity and specificity. The inventor deposited the cell line in the General Microbiology Center of China Microorganism Culture Collection Administration on March 27, 2024, with the deposit number CGMCC No.45832.
[0023] Subsequently, the inventors sequenced the monoclonal antibody secreted by the mouse hybridoma cell line CGMCC No.45832 and analyzed the immunoglobulin domain sequence, and found that its heavy chain variable region amino acid sequence was: EVQLVESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRNKAN NHATFYAESVKGRFTISRDDSKSSVFLQMHSLRAEGTGIYYCTRRRNYFDYWGQGTT LTVS (SEQ ID NO.1), wherein the CDR1 amino acid sequence was GFTFSDAW (SEQ ID NO.2), the CDR2 amino acid sequence was IRNKANNHAT (SEQ ID NO.3), and the CDR3 amino acid sequence was TRRRNYFDY (SEQ ID NO.4). The amino acid sequence of the light chain variable region is: DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLE SGVPARFSGSGSGTHFTLNIHPVEEEDAATYYCQHIRELTRSEGAPSWKS (SEQ ID NO.5), wherein the amino acid sequence of CDR1 is KSVSTSGYSY (SEQ ID NO.6), the amino acid sequence of CDR2 is LVS, and the amino acid sequence of CDR3 is QHIRELTR (SEQ ID NO.7).
[0024] The inventors measured the affinity and specificity of the above monoclonal antibody for human oxLDL detection by enzyme-linked immunosorbent assay and fluorescent immunochromatography, and found that its minimum detection limit was 2 ng / mL, significantly higher than 16 ng / mL of the commercial kit, and had high sensitivity and specificity for oxLDL detection.
[0025] It is well known in the art that the heavy chain CDR region and light chain CDR region of an antibody are important amino acid sequence regions for recognizing and binding to the corresponding antigen, and a conservative amino acid substitution in the amino acid sequence of the above CDR region generally does not change the structure of the protein, so a single conservative amino acid substitution in the above region may still have the property of binding to the corresponding antigen. Therefore, the monoclonal antibody or its antigen-binding fragment obtained after a conservative amino acid substitution in the heavy chain CDR1 and / or the heavy chain CDR2 and / or the heavy chain CDR3 and / or the light chain CDR1 and / or the light chain CDR2 and / or the light chain CDR3 can still recognize and bind to human oxLDL. In the patent application of the present invention, conservative amino acid substitution refers to the replacement of a certain amino acid in a protein by another chemically similar amino acid, such as the mutual substitution between aromatic amino acids Phe, Trp, and Tyr, the mutual substitution between aliphatic amino acids Ala, Gly, Leu, Ile, and Val, the mutual substitution between polar amino acids Gln and Asn, the mutual substitution between basic amino acids Lys, Arg, and His, the mutual substitution between acidic amino acids Asp and Glu, and the mutual substitution between hydroxyl amino acids Ser and Thr, etc.
[0026] A person skilled in the art can also prepare various antibody fragments capable of binding to human oxLDL, i.e., antigen-binding fragments, such as but not limited to Fab, Fab', and F(ab')2, from the monoclonal antibodies of the present invention by using the existing technology in the art. The Fab fragment is a region in the antibody structure that can bind to an antigen, and is composed of a complete heavy chain and a variable region VH and a constant region CH1 domain (Fd segment) of a light chain. Both the heavy chain and the light chain have a constant region and a variable region, and there is a disulfide bond between the light and heavy chains. The antigen-binding fragment can be prepared as follows, for example, after enzymatic hydrolysis with papain, the antibody IgG is degraded into two Fab fragments and an Fc fragment. Under the action of pepsin, the antibody IgG is degraded into an F(ab')2 fragment and a pFc' fragment, and the F(ab')2 fragment is further reduced to form two Fab' fragments. Because the above-mentioned antigen-binding fragments can still bind to the corresponding antigen, they can be used to prepare products for detecting human oxLDL.
[0027] Those skilled in the art can also prepare single-chain antibodies (scFv) from the monoclonal antibodies of the present invention by the existing technology in the art. Single-chain antibodies are antibodies formed by connecting the heavy chain variable region and the light chain variable region of the antibody through a short peptide linker of several amino acids. They have only one chain and are artificially synthesized antibodies. The length and amino acid composition of the short peptide linker are well known in the art, and the short peptide linker that can be used for the monoclonal antibodies of the present invention can be determined by simple repeated experiments. Single-chain antibodies can be expressed in, for example, Escherichia coli by genetic engineering technology. The single-chain antibodies of the present invention prepared in this way have the property of binding to human oxLDL and can be used in the detection of human oxLDL.
[0028] A person skilled in the art can design and synthesize a nucleic acid molecule encoding the above-mentioned monoclonal antibody against human oxLDL based on the amino acid sequence of the variable region of the monoclonal antibody against human oxLDL, and can also insert the synthesized nucleic acid molecule into a nucleic acid vector to construct an expression vector, which can express the monoclonal antibody against human oxLDL or its antigen-binding fragment. A person skilled in the art can also introduce the synthesized nucleic acid molecule or the constructed expression vector into an organism such as a cell, a bacterium, a yeast, etc. to obtain a recombinant, and produce the antibody or its antigen-binding fragment of the present invention through the expression of the above-mentioned recombinant, so that the expressed antibody or its antigen-binding fragment can bind to and recognize human oxLDL, so the above-mentioned nucleic acid molecule, expression vector and recombinant are within the scope of protection of the claims of the present invention. Moreover, the above-mentioned technologies are all well-known technologies in the art, and can be carried out by a person skilled in the art without creative labor.
[0029] As described above, the antibody or antigen-binding fragment thereof of the present invention can recognize and bind to human oxLDL, and thus can be used to prepare a kit for detecting human oxLDL. The kit can be any type of kit that utilizes the binding reaction between the antibody or antigen-binding fragment thereof of the present invention and human oxLDL, such as but not limited to enzyme-linked immunosorbent assay, fluorescent immunochromatography, colloidal gold immunochromatography, chemiluminescence, immunoblotting, and immunohistochemistry.
[0030] In order to explain the technical content, achieved objectives and effects of the technical solution in detail, the following is a description in conjunction with specific embodiments.
[0031] Example 1: Screening of oxLDL antigens for immunization and screening
[0032] First, oxidized low-density lipoprotein (oxLDL) antigens were purchased from different manufacturers, including Beijing Solaibao Biotechnology Co., Ltd. (Cat. No. H7950), Beijing Biolabo Technology Co., Ltd. (Cat. No. QN0279), Cell Biolabs (Cat. No. STA-369), and Yisheng Biotechnology (Shanghai) Co., Ltd. (Cat. No. 20605ES05). At the same time, an oxidized low-density lipoprotein assay kit (enzyme-linked immunosorbent assay) produced by Swedish Mercodia AB was purchased (National Medical Device Injection No. 20162402874), and the serial dilutions of the four purchased oxLDL antigens were tested in strict accordance with the test steps in the kit instructions. The results are shown in Table 1. Among the four oxLDL antigens, the measured values of the oxLDL antigen with item number H7950 (hereinafter referred to as H7950 or H7950 oxLDL antigen) and the oxLDL antigen with item number 20605ES05 (hereinafter referred to as 20605ES05 or 20605ES05 oxLDL antigen) at a concentration of 0.2 μg / ml were significantly higher than the measured values of the oxLDL antigen with QN0279 (hereinafter referred to as QN0279 or QN0279 oxLDL antigen) and the oxLDL antigen with item number STA-369 (hereinafter referred to as STA-369 or STA-369oxLDL antigen) at the same concentration, indicating that the antigen activity of H7950 and 20605ES05 was significantly higher than that of QN0279 and STA-369. Therefore, H7950 was selected as the immunization antigen and 20605ES05 was selected as the monoclonal antibody screening antigen, so as to easily induce the production of monoclonal antibodies and avoid cross-reactions in the monoclonal antibody preparation process as much as possible.
[0033] Table 1 Results of oxLDL antigen screening and identification
[0034]
[0035] Example 2: Preparation of rabbit anti-oxLDL polyclonal antibodies
[0036] Healthy male white rabbits were selected, 1 mg H7950 oxLDL antigen was mixed with 1 ml Freund's complete adjuvant, and after thorough emulsification with a blender, multiple subcutaneous injections were performed on both sides of the rabbit spine, with 0.2 ml injected at each point; 1 mg antigen was mixed with 1 ml Freund's incomplete adjuvant, and after thorough emulsification with a blender, a second immunization was performed at different points in the above-mentioned parts; a third booster immunization was performed 4 weeks later for the preparation of polyclonal antibody serum. Blood was collected from the heart 1 week later, and serum was collected by centrifugation at 5000 rpm for 15 minutes, which was then aliquoted and stored in a -20°C refrigerator for later use. 20605ES05 oxLDL antigen was used as the detection antigen to coat the enzyme-linked plate, and the titer of rabbit anti-oxLDL polyclonal antibody was detected by indirect ELISA. The specific method is as follows: dilute 20605ES05 oxLDL antigen with carbonate coating buffer to a concentration of 2.0 μg / ml, coat 100 μl per well, and incubate at 4°C overnight; wash the plate twice with washing solution; add 110 μl / well blocking solution to block at room temperature for 6 hours; wash the plate 5 times with washing solution. Add 100 μl of serially diluted rabbit serum or pre-immune control serum to each well, incubate at room temperature for 45 minutes, and discard the solution. Wash the plate 5 times, invert the washed ELISA plate on absorbent paper, and pat it vigorously to remove excess washing solution. Add 100 μl / well HRP-labeled goat anti-rabbit IgG antibody and incubate at room temperature for 45 minutes. Wash the plate 5 times. Add 50 μL each of TMB colorimetric solution A (13.6 g sodium acetate, 1.6 g citric acid, 0.3 ml 30% hydrogen peroxide, distilled water to 500 mL) and solution B (0.2 g disodium ethylenediaminetetraacetic acid, 0.95 g citric acid, 50 mL glycerol, 0.15 g TMB dissolved in 3 ml DMSO, distilled water to 500 mL) to each well, and color develop for 15 min at room temperature in the dark. Add 50 μL / well of 2M H2SO4 stop solution to terminate the reaction. Set the detection wavelength of the microplate reader to 450 nm, measure the OD value of each well, and read the value within 10 minutes after termination. The results are as follows: Figure 1 As shown, the titer of the prepared rabbit anti-oxLDL polyclonal antibody is 1:512000. The rabbit anti-oxLDL polyclonal antibody is purified and used as a backup.
[0037] Example 3: Horseradish peroxidase labeling of rabbit anti-oxLDL polyclonal antibody
[0038] The anti-oxLDL polyclonal antibody obtained in Example 2 was labeled with horseradish peroxidase (HRP) using a modified sodium periodate method. The specific operation was as follows: 5 mg of HRP was dissolved in 0.5 mL of deionized water, and 1 mL of 0.06 mol / L NaIO4 was added and stirred gently at room temperature in the dark for 30 min, and the liquid was yellow-green; 1 mL of 0.16 mol / L ethylene glycol was added and stirred gently at room temperature for 1 hour to terminate the oxidation reaction; the solution was placed in a dialysis bag and dialyzed overnight at 4°C with 1000 mL of 0.01 mol / L, pH 9.5 carbonate buffer solution, and the solution was changed 3 times; 1 mL of carbonate buffer solution containing 5 mg of polyclonal antibody was added to 3 mL of aldehyde HRP solution, and the solution was stirred gently at room temperature in the dark for 2 to 3 hours; 5 mg NaHB4, 4℃ overnight; put into dialysis bag, dialyze with 1000mL of 0.01mol / L, pH7.2 phosphate buffer at 4℃ for 24 hours, change the liquid 3 times; centrifuge at 3000r / min for 30min, remove the precipitate, add an equal amount of glycerol to the supernatant, divide into small portions, and store at low temperature for later use.
[0039] Example 4: Preparation of anti-oxLDL monoclonal antibodies
[0040] H7950 oxLDL antigen was used as the immunogen, and 8-week-old BALB / c female mice were used. 120 μg / mouse antigen was added with an equal amount of Freund's complete adjuvant, and the mice were thoroughly emulsified by a blender and then injected subcutaneously and intraperitoneally on the back to immunize the mice. The second and third immunizations were performed 4 weeks and 8 weeks later, respectively. 80 μg / mouse antigen was added with incomplete Freund's adjuvant, and the mice were thoroughly emulsified by a blender and then injected subcutaneously and intraperitoneally on the back to immunize the mice. Seven days after the third immunization, blood was collected from the tail vein of the mice to detect the titer of the immune serum, and the mice with the highest titer were selected for intraperitoneal booster immunization (60 μg / mouse). After 3 days, spleen cells were taken for fusion. SP20 myeloma cells were resuscitated and cultured until they were in the logarithmic growth phase. The spleens of the immunized BALB / c mice were taken, and spleen cell suspensions were prepared. Take the above spleen cells and myeloma cells in a ratio of 5:1, mix them in serum-free DMEM medium, centrifuge at 1500rpm for 5 minutes, fully absorb the supernatant, gently shake the bottom of the centrifuge tube to disperse the cells, add 1mL of preheated 50% PEG fusion cells within 1 minute, shake gently while adding, let stand for 90 seconds after adding, add serum-free DMEM medium to terminate fusion, let stand at 37℃ for 10min, centrifuge at 1500rpm for 5 minutes, suspend the precipitate with HAT medium, divide it into 96-well cell plates containing feeder cells, and culture in a cell culture incubator at 37℃ and 5% CO2. After 5 days of culture in the cell culture incubator, replace the medium with HAT medium once, and replace the medium with HAT medium on the 10th day. When the fusion cells cover 40%-60% of the bottom of the well, take the cell culture supernatant and dilute it serially with PBS, and the dilution multiples are 400, 800, 1600, 3200, 6400 and 12800 respectively. The indirect ELISA method was used to screen positive clones. The specific method was as follows: 20605ES05 oxLDL antigen was diluted with carbonate coating buffer to a concentration of 2.0 μg / ml, and 100 μl was coated in each well at 4°C overnight; the plate was washed twice with washing solution; 110 μl / well blocking solution was added to block at room temperature for 6 hours; the plate was washed 5 times with washing solution. After adding 100 μl of sample diluent to each well, 10 μl of cell culture supernatant was added respectively, incubated at room temperature for 60 min, and the solution was discarded. The plate was washed 5 times, the washed ELISA plate was inverted on absorbent paper and patted dry, 100 μl / well HRP-labeled goat anti-mouse IgG antibody was added, and incubated at room temperature for 45 min. The plate was washed 5 times. 50 μL of TMB color development solution A and B solution were added to each well, and the color was developed at room temperature in the dark for 15 min. 50 μL of 2MH2SO4 stop solution was added to each well to terminate the reaction. Set the detection wavelength of the microplate reader to 450 nm, measure the OD value of each well, and read the value within 10 minutes after termination.
[0041] A total of 19 positive clones were obtained, and the titers of all monoclonal cell culture supernatants exceeded 1:3200. Among them, the titers of two monoclonal cell culture supernatants reached 1:12800, namely mouse polyclonal cell lines DF868 and AB334. The mouse polyclonal cell line DF868 has been deposited in the General Microbiology Center of China Microorganism Culture Collection (CGMCC), the registration number of the collection center is CGMCC No.45832, and the preservation date is March 27, 2024.
[0042] Example 5: Determination of the affinity of anti-oxLDL monoclonal antibodies
[0043] The BIACORE3000 biomolecular interaction analyzer was used to perform Biocore kinetic experiments to analyze the affinity of the two anti-oxLDL monoclonal antibodies DF868 and AB334 obtained in Example 4 to the 20605ES05 oxLDL antigen and human low-density lipoprotein LDL (item number 20613ES05, purchased from Yishen Biotechnology (Shanghai) Co., Ltd., hereinafter referred to as 20613ES05). The two monoclonal antibody hybridoma cell lines were cultured in 1640 culture medium containing 10% fetal bovine serum. Each BALB / c male mouse was intraperitoneally injected with 0.5 mL of liquid paraffin. After 10 days, the cells were collected and resuspended in 10 mL of normal saline, and each mouse was intraperitoneally injected with 0.5 mL (cell density was approximately 1×10 7 / mL). After 2 weeks, ascites was collected. Antibody purification was performed using the Melon GelMonoclonal IgG Purification Kit from Thermo Company. The antibody protein concentration was determined by a UV spectrophotometer, and the antibody concentration was adjusted to 1.0 mg / mL using a phosphate antibody diluent. Two monoclonal antibodies of the same concentration were diluted 1:100 with phosphate buffer, and antibodies were introduced at a rate of 5 μL / min for antibody binding, and the introduction time was 1.5 min. Subsequently, 1.0 mg / mL of 20605ES05oxLDL antigen and 20613ES05 human low-density lipoprotein LDL were introduced at a rate of 30 μl / min for binding, and the introduction time was 8 min. The binding time was the same as the dissociation time. The data of Biocore binding kinetics experiments are shown in Table 2, where ka represents the binding rate constant, i.e., the binding speed of the reaction molecules; kd represents the dissociation rate constant, i.e., the dissociation speed of the reaction molecular complex; and KD represents the dissociation equilibrium constant (KD = kd / ka). Generally, the smaller the KD value, the higher the affinity between the two.
[0044] Table 2 Biocore kinetics analysis of monoclonal antibody affinity
[0045]
[0046] The results in Table 2 show that the binding rate constant of monoclonal antibody DF868 to oxLDL antigen is significantly higher than that to non-oxidized LDL antigen, and the dissociation equilibrium constant to oxLDL antigen is significantly greater than that to non-oxidized LDL antigen, indicating that monoclonal antibody DF868 can specifically bind to oxLDL antigen; while the binding rate constants and dissociation equilibrium constants of monoclonal antibody AB334 to oxLDL antigen and non-oxidized LDL antigen are similar, indicating that monoclonal antibody AB334 cannot distinguish between oxLDL antigen and non-oxidized LDL antigen.
[0047] Example 6: Determination of specificity of anti-oxLDL monoclonal antibodies
[0048] The mouse anti-oxLDL monoclonal antibodies DF868 and AB334 of the present invention were used as coating antibodies, and the rabbit anti-oxLDL polyclonal antibody was used as the detection antibody to establish a double antibody sandwich detection method for human oxLDL antigen. The specific steps are to coat the enzyme-linked plate with mouse anti-oxLDL monoclonal antibodies at a concentration of 2.0 μg / mL, 100 μL per well, and keep overnight at 4°C; wash the plate twice with washing solution, 200 μL / well; add 110 μL / well blocking solution to block at room temperature for 6 hours; wash the plate 5 times with washing solution, 200 μL / well. 100 μL of 2.0 μg / mL human oxLDL antigen (Cat. No. 20605ES05), LDL antigen (Cat. No. 20613ES05), human very low density lipoprotein (VLDL, from Yisheng Biotechnology (Shanghai) Co., Ltd., Cat. No. 20617ES05) or human high density lipoprotein (HDL, from Yisheng Biotechnology (Shanghai) Co., Ltd., Cat. No. 20610ES05) was added to each well, and each antigen was tested in 5 wells. Incubate at room temperature for 1.5 hours and discard the solution. Wash the plate 5 times with washing solution, 200 μL per well. Add 100 μL of HRP-rabbit anti-oxLDL polyclonal antibody enzyme conjugate to each well and incubate at room temperature for 45 minutes. Wash the plate 5 times, pat dry, add 50 μL of TMB color development solution A and B solution to each well, and color at room temperature in the dark for 15 minutes. Add 50 μL of 2M H2SO4 stop solution to each well to terminate the reaction. The OD450 nm value of each well was measured by microplate reader within 10 minutes. Figure 2 As shown, the monoclonal antibody DF868 of the present invention is highly specific to oxLDL and does not cross-react with LDL, VLDL and HDL; while the monoclonal antibody AB334 cross-reacts with LDL, VLDL and HDL.
[0049] Example 7: Sensitivity of ELISA for detecting oxLDL
[0050] The mouse anti-oxLDL monoclonal antibody DF868 of the present invention was used as a coating antibody, and the rabbit anti-oxLDL polyclonal antibody was used as a detection antibody. A double antibody sandwich method was established to detect human oxLDL antigen, and the detection sensitivity was evaluated. The specific steps are to coat the enzyme-linked plate with mouse anti-oxLDL monoclonal antibody at a concentration of 2.0 μg / mL, 100 μL per well, and incubate at 4°C overnight; wash the plate twice with a washing solution, 200 μL / well; add 110 μL / well blocking solution to block at room temperature for 6 hours; wash the plate 5 times with a washing solution, 200 μL / well. Add 100 μL of serially diluted human oxLDL antigen to each well, incubate at room temperature for 2 hours, and discard the solution. Wash the plate 5 times with a washing solution, 200 μL per well. Add 100 μL of HRP-rabbit anti-oxLDL polyclonal antibody enzyme conjugate to each well and incubate at room temperature for 45 minutes. Wash the plate 5 times, pat dry, add 50 μL of TMB colorimetric solution A and solution B to each well, and color at room temperature and in the dark for 15 minutes. Add 50 μL of 2M H2SO4 stop solution to each well to terminate the reaction. The OD450nm value of each well was measured by a microplate reader within 10 minutes. At the same time, the diluted human oxLDL antigen was detected in parallel using the oxidized low-density lipoprotein assay kit (enzyme-linked immunosorbent assay) produced by Mercodia AB (National Medical Device Injection No. 20162402874). The results are shown in Table 3. With a Cutoff value of 0.15, the DF868 monoclonal antibody of the present invention was used as the coating antibody, and the rabbit anti-oxLDL polyclonal antibody was used as the detection antibody. The minimum detectable concentration of human oxLDL antigen detected by the double antibody sandwich method was 8.0 ng / mL, and the minimum detectable concentration of the Mercodia AB enzyme-linked immunosorbent assay kit was 16 ng / mL. The detection sensitivity of the human oxLDL double antibody sandwich detection method established using the DF868 monoclonal antibody of the present invention is significantly higher than that of the existing commercial kit.
[0051] Table 3 Detection sensitivity of oxLDL enzyme-linked immunosorbent assay (OD450nm)
[0052]
[0053]
[0054] Example 8: Sensitivity of fluorescent immunochromatography for detecting oxLDL
[0055] Based on the double antibody sandwich principle, the fluorescent microspheres were labeled with the mouse anti-oxLDL monoclonal antibody DF868 of the present invention, and the rabbit anti-oxLDL polyclonal antibody prepared by the present invention was coated on the nitrocellulose membrane, and the oxLDL content in the sample was quantitatively determined by fluorescent immunochromatography to evaluate the detection sensitivity. The specific operation is: take 100 μL of serially diluted human oxLDL antigen, vertically drip it to the sample addition position of the test card, and place it at room temperature for reaction for 15 minutes. The oxLDL antigen in the sample and the anti-oxLDL monoclonal antibody labeled with fluorescent microspheres combine to form an oxLDL antigen-oxLDL antibody immune complex. The immune complex and the chicken IgY antibody labeled with fluorescent microspheres (purchased from Beijing Biolabor Technology Co., Ltd., item number F050315) move forward along the nitrocellulose membrane with chromatography. When it reaches the detection area (T line), the reaction complex is captured by the rabbit anti-oxLDL polyclonal antibody on the nitrocellulose membrane detection line, and the chicken IgY antibody labeled with fluorescent microspheres is captured by the goat anti-chicken IgY antibody (purchased from Beijing Biolabor Technology Co., Ltd., item number F020229) coated on the nitrocellulose membrane in the quality control area (C line). The ratio of the fluorescence value of the T line to the fluorescence value of the C line (T / C) is calculated. The amount of oxLDL captured in the sample is positively correlated with the signal intensity of the fluorescent antibody. The cutoff value is three times the T / C value of the sample diluent. The minimum detectable concentration of human oxLDL antigen determined by the fluorescent immunochromatographic double antibody sandwich method established using the DF868 monoclonal antibody of the present invention as the coating antibody is 2 ng / mL, and the detection sensitivity is significantly higher than that of the existing commercial Mercodia AB enzyme-linked immunosorbent assay kit. The results are shown in Table 4.
[0056] Table 4 Detection sensitivity of oxLDL fluorescence immunochromatography detection method (T / C value)
[0057]
[0058] Example 9: Subtype analysis of anti-oxLDL monoclonal antibody DF868
[0059] The mouse antibody subtype rapid test card (Cat. No. ATG-ISO-M8a) from Antaiji (Beijing) Biotechnology Co., Ltd. was used to identify the heavy chain and light chain subtypes of mouse antibodies. First, the antibody was diluted to 1 μg / mL with PBS, and then 100 μl of the diluted antibody was added to each well. After standing for 5-10 minutes, the results were observed and recorded. Figure 3 As shown, the anti-oxLDL monoclonal antibody DF868 is of mouse IgG1 subtype, and the antibody light chain is of Igκ subtype.
[0060] Example 10: Determination of variable region sequence of anti-oxLDL monoclonal antibody DF868
[0061] The anti-oxLDL monoclonal antibody DF868 hybridoma cell line was obtained, and the total RNA of the hybridoma cells was extracted by the Trizol method. After reverse transcription of cDNA using the High Capacity cDNA Rever Transcription Kit of Thermo Fisher, the heavy and light chain primers of the antibody were designed and synthesized by Beijing Qingke Biotechnology Co., Ltd. according to the mouse monoclonal antibody primer sequence in Modern Immunology Experimental Techniques (Hubei Science and Technology Press, 2nd edition). PCR amplification (amplification program: 95℃ preheating for 1min, 30 cycles (95℃30s, 58℃30s, 72℃45s), and finally 72℃ extension for 5min), connected to the pMD18-T vector, expressed in Escherichia coli JM109, and positive clones were selected for sequencing. The determined sequence was compared and analyzed on the BLAST website (https: / / www.ncbi.nlm.nih.gov / igblast / ) with the mouse monoclonal antibody CDR region sequence.
[0062] After sequence analysis, it was found that the amino acid sequence of the heavy chain variable region was 117 amino acids, and its sequence was as follows: EVQLVESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRNKAN NHATFYAESVKGRFTISRDDSKSSVFLQMHSLRAEGTGIYYCTRRRNYFDYWGQGTT LTVS (SEQ ID NO.1), wherein CDR1 was located at 26-33aa, and the amino acid sequence was GFTFSDAW (SEQ ID NO.2), CDR2 was located at 51-60aa, and the amino acid sequence was IRNKANNHAT (SEQ IDNO.3), and CDR3 was located at 99-107aa, and the amino acid sequence was TRRRNYFDY (SEQ ID NO.4).
[0063] The amino acid sequence of the light chain variable region is 108 amino acids, and its sequence is as follows: DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLE SGVPARFSGSGSGTHFTLNIHPVEEEDAATYYCQHIRELTRSEGAPSWKS (SEQ ID NO.5, wherein CDR1 is located at 27-36aa, and the amino acid sequence is KSVSTSGYSY (SEQ ID NO.6); CDR2 is located at 54-56aa, and the amino acid sequence is LVS; CDR3 is located at 93-100aa, and the amino acid sequence is QHIRELTR (SEQ ID NO.7).
Claims
1. A monoclonal antibody or antigen-binding fragment thereof against human oxidized low-density lipoprotein, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, and the light chain variable region comprises a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein: The amino acid sequence of the heavy chain CDR1 is the sequence shown in SEQ ID NO.2; The amino acid sequence of the heavy chain CDR2 is the sequence shown in SEQ ID NO.3; The amino acid sequence of the heavy chain CDR3 is the sequence shown in SEQ ID NO.4; The amino acid sequence of the light chain CDR1 is the sequence shown in SEQ ID NO.6; The amino acid sequence of the light chain CDR2 is the sequence LVS; The amino acid sequence of the light chain CDR3 is the sequence shown in SEQ ID NO.
7.
2. The monoclonal antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The amino acid sequence of the heavy chain variable region is the sequence shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is the sequence shown in SEQ ID NO.
5.
3. The monoclonal antibody or antigen-binding fragment thereof according to claim 1 or 2, characterized in that: The antibody or antigen-binding fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a single-chain antibody or a humanized antibody.
4. A nucleic acid molecule, characterized in that The nucleic acid comprises a nucleic acid encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.
5. An expression vector, characterized in that: The expression vector comprises the nucleic acid molecule of claim 4.
6. A recombinant cell, bacterium or yeast, characterized in that: The recombinant cell, bacterium or yeast comprises the nucleic acid molecule of claim 4 or the expression vector of claim 5.
7. A hybridoma cell line, characterized in that: The hybridoma cell line is a mouse hybridoma cell line DF868, and its deposit number is CGMCC No. 45832.
8. Use of the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 in the preparation of a product for detecting human oxidized low-density lipoprotein.
9. A kit for detecting human oxidized low-density lipoprotein, characterized in that: The method comprises the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.
